Outfitter Financial LLC boosted its position in Pacira BioSciences, Inc. (NASDAQ:PCRX – Free Report) by 5.7% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 20,190 shares of the company’s stock after buying an additional 1,095 shares during the quarter. Outfitter Financial LLC’s holdings in Pacira BioSciences were worth $578,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also bought and sold shares of the company. Jane Street Group LLC increased its position in Pacira BioSciences by 1,780.2% in the first quarter. Jane Street Group LLC now owns 187,531 shares of the company’s stock worth $5,480,000 after buying an additional 177,557 shares during the last quarter. Cobalt Capital Management Inc. purchased a new position in shares of Pacira BioSciences in the fourth quarter valued at $3,037,000. Legato Capital Management LLC grew its position in shares of Pacira BioSciences by 74.0% in the second quarter. Legato Capital Management LLC now owns 52,913 shares of the company’s stock valued at $1,514,000 after purchasing an additional 22,497 shares in the last quarter. National Bank of Canada FI purchased a new position in shares of Pacira BioSciences in the fourth quarter valued at $966,000. Finally, Bridge City Capital LLC purchased a new position in shares of Pacira BioSciences in the first quarter valued at $1,810,000. 99.73% of the stock is owned by hedge funds and other institutional investors.
Insider Activity at Pacira BioSciences
In other news, SVP Lauren Riker sold 3,970 shares of the stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $28.72, for a total transaction of $114,018.40. Following the transaction, the senior vice president now directly owns 38,075 shares of the company’s stock, valued at approximately $1,093,514. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, insider Jonathan Slonin sold 5,012 shares of the company’s stock in a transaction on Tuesday, June 11th. The stock was sold at an average price of $28.57, for a total value of $143,192.84. Following the completion of the sale, the insider now directly owns 44,569 shares in the company, valued at approximately $1,273,336.33. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Lauren Riker sold 3,970 shares of the company’s stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $28.72, for a total value of $114,018.40. Following the completion of the sale, the senior vice president now owns 38,075 shares of the company’s stock, valued at $1,093,514. The disclosure for this sale can be found here. In the last three months, insiders have acquired 11,176 shares of company stock valued at $136,240 and have sold 22,095 shares valued at $621,118. 6.40% of the stock is currently owned by insiders.
Pacira BioSciences Stock Up 1.3 %
Pacira BioSciences (NASDAQ:PCRX – Get Free Report) last released its quarterly earnings data on Tuesday, July 30th. The company reported $0.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.53 by $0.11. The business had revenue of $178.02 million for the quarter, compared to analysts’ expectations of $173.31 million. Pacira BioSciences had a return on equity of 13.22% and a net margin of 9.21%. On average, sell-side analysts forecast that Pacira BioSciences, Inc. will post 2.26 EPS for the current year.
Wall Street Analyst Weigh In
Several research firms have recently commented on PCRX. Royal Bank of Canada downgraded Pacira BioSciences from an “outperform” rating to a “sector perform” rating and decreased their price objective for the stock from $37.00 to $14.00 in a report on Monday, August 12th. HC Wainwright decreased their price objective on Pacira BioSciences from $57.00 to $39.00 and set a “buy” rating on the stock in a report on Monday, August 12th. JPMorgan Chase & Co. reiterated an “underweight” rating and issued a $10.00 price objective (down previously from $45.00) on shares of Pacira BioSciences in a report on Monday, August 12th. Truist Financial downgraded Pacira BioSciences from a “buy” rating to a “sell” rating and reduced their price target for the company from $30.00 to $8.00 in a report on Tuesday, August 13th. Finally, StockNews.com downgraded Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a report on Monday, August 12th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $24.78.
Read Our Latest Stock Analysis on PCRX
Pacira BioSciences Company Profile
Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.
See Also
- Five stocks we like better than Pacira BioSciences
- How to Use Stock Screeners to Find Stocks
- Birkenstock’s Sudden Slide—Why It Might Be Your Next Big Win
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Why Dell Can Continue Winning in AI and Beyond
- What Are Growth Stocks and Investing in Them
- Veeva’s Stock Jumps on Stellar Q2 Results—Don’t Miss Out
Receive News & Ratings for Pacira BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.